Concepedia

Aggregate Safety Data Analysis

Aggregate Safety Data Analysis is a systematic pharmacovigilance methodology that evaluates cumulative safety data from multiple sources or studies to identify, quantify, and interpret adverse event patterns and emerging risks associated with a medicinal product over time.

18

Publications

1.2K

Citations

231

Authors

152

Institutions

Publications per year

2017–2026

6

Parents

Publications

18

Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder

Philip G. Janicak, John P. O’Reardon, Shirlene Sampson et al. · The Journal of Clinical Psychiatry · 2008 · 235 citations

, , +15

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

Kayvon Modjarrad, Leyi Lin, Sarah L. George et al. · The Lancet · 2017 · 196 citations · Full text

, , +17

Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team

Brenda Crowe, H. Amy Xia, Jesse A. Berlin et al. · Clinical Trials · 2009 · 120 citations

, , +16

Aggregate nonparametric safety analysis of traffic zones

Chowdhury Siddiqui, Mohamed Abdel‐Aty, Helai Huang · Accident Analysis & Prevention · 2011 · 77 citations · Full text

, , +10

Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa

Yolanda Guerra Mendoza, Elodie Garric, Amanda Leach et al. · Human Vaccines & Immunotherapeutics · 2019 · 66 citations · Full text

, , +17

1–5 of 18

Authors

231

  1. RC
    Robert C Schriver

    Sanofi (United States), United States

    2 publications · 142 citations

    2

    h-index

  2. HA
    H. Amy Xia

    Amgen (United States), United States

    2 publications · 142 citations

    2

    h-index

  3. JK
    Juergen Kuebler

    AstraZeneca (United Kingdom), United Kingdom

    2 publications · 140 citations

    2

    h-index

  4. DB
    David B. Hall

    Boehringer Ingelheim (United States), United States

    2 publications · 142 citations

    2

    h-index

  5. MO
    Manfred Oster

    Sanofi (United States), United States

    2 publications · 142 citations

    2

    h-index

1–5 of 231

Institutions

152

  1. GlaxoSmithKline (United States)

    Philadelphia, United States

    3 h-index

    3 publications

    159 citations

  2. University of Pennsylvania

    Philadelphia, United States

    3 h-index

    4 publications

    317 citations

  3. United States Food and Drug Administration

    Silver Spring, United States

    3 h-index

    3 publications

    168 citations

  4. Beth Israel Deaconess Medical Center

    Boston, United States

    3 h-index

    18 publications

    2.3K citations

  5. Amgen (United States)

    Thousand Oaks, United States

    3 h-index

    3 publications

    159 citations

  6. Merck & Co., Inc., Rahway, NJ, USA (United States)

    Rahway, United States

    3 h-index

    11 publications

    685 citations

  7. Eli Lilly (United States)

    Indianapolis, United States

    2 h-index

    2 publications

    142 citations

  8. AbbVie (United States)

    North Chicago, United States

    2 h-index

    3 publications

    54 citations

1–8 of 152

Venues

  1. Clinical Trials

    2 publications · 142 citations

    2

    h-index

  2. 1

    h-index

  3. Statistics in Biopharmaceutical Research

    SBR · 1 publications · 17 citations

    1

    h-index

  4. European Journal of Cancer

    1 publications · 44 citations

    1

    h-index

  5. EBioMedicine

    1 publications · 22 citations

    1

    h-index

1–5